Page 191 - Read Online
P. 191

Berezin et al. Vessel Plus 2020;4:15  I  http://dx.doi.org/10.20517/2574-1209.2020.03                                                  Page 9 of 13

               which promotes endothelial dysfunction and accelerates atherosclerosis through the high-affinity receptor
                     [92]
               BLTR1 . In fact, the presence of dysregulated inflammatory molecules on the surface of the endothelial
               cell layer was associated with increased coagulation due to over-expression of the glycoprotein (GP) IIb/
               IIIa (integrin αIIbβ3) receptor, anomalous clot formation or shaping amyloid fibrin [93,94] . Importantly,
               the GPIIb/IIIa receptors were additionally shed into EVs and transferred as cargo to the target cells for
               translation of activation signals remotely. Another finding has demonstrated that heat shock protein
               27 (HSP27) packaged into EVs via activating TLR-4/NF-κB in the target cells can attenuate endothelial
               function, reduce vascular and plaque inflammation, lower cholesterol levels and suppress atherogenesis
                              [95]
               in animal models . However, the angiopoetic role of activated endothelial cell-derived EVs is not always
               considered as having a positive impact on the endothelium. For instance, neovascularization of the
               shoulder region of the plaque’s cap was associated with instability of the atheroma due to the increased
               risk of rupture [94,96] . There are several excellent reviews that are dedicated the role of EVs in vascular
               homeostasis and its relation to CV disease development [97,98] . Thus, EVs promote the function of target cells
               through the transfer of surface integrins and receptors, cellular fusion and the delivery of various active
               molecules.


               EVs as diagnostic and predictive biomarkers of atherosclerosis
               The diagnostic and predictive roles of endothelial cell-derived EVs in atherosclerosis and MACEs are
                        [99]
               uncertain . However, there has been progress in the diagnosis, prognostication and treatment of CV
               diseases with EVs [100] . For instance, HSP27 packaged in endothelial cell-derived EVs was found to be a
                                                                                                    [95]
               predictor of a lower CV risk among patients having a heart attack, stroke, or death from CV disease . The
               imbalance between activated and apoptotic endothelial cell-derived EVs has provided additional prognostic
               information for patients with established CV disease, including acute myocardial infarction, acute coronary
               syndrome, ischemic heart failure, MACEs, and arrhythmias, as well as individuals with metabolic diseases
               having a higher risk of CV events and disease [101-104] .

               Future directions toward the role of EVs in atherosclerosis
               EVs have demonstrated a pivotal role in transferring numerous bioactive molecules, supporting cell-to-cell
               cooperation, and regulate gene expression in target cells. EVs-based therapeutic regenerative strategies may
               thus be used to attenuate tissue injury and promote vascular regeneration and repair [105,106] . Accumulating
               evidence implicates EVs in the development and progression of atherosclerosis, and creates the possibility
               of using EVs for personalized therapeutic strategies. Therefore, single-EV analysis may identify signatures
               of exosome-derived DNA/non-coding RNAs including microRNA, regulator proteins, and other
               components both as diagnostic and predictive biomarkers in atherosclerosis [107] . Large clinical studies are
               required for further elucidation of whether EVs can be excellent options for point-of-care diagnosis and
               individual treatment.

               CONCLUSION
               EVs could be promising biomarkers with both diagnostic and predictive values, while their number,
               content, immune phenotype and origin may provide more useful information about the pathophysiology of
               atherosclerosis and help stratify patients at risk of MACEs. The emergence of endothelial cell-derived EVs
               provide favorable and promising strategies, not only for CV risk stratification in vulnerable populations but
               for individualized treatment of atherosclerosis and other CV diseases.


               DECLARATIONS
               Authors’ contributions
               Participated in drafting the article, revised it critically for important intellectual content: Berezin AE
               Gave final approval of the version to be submitted: Berezin AA
               Both authors make eqaual contributions to conception and design, searchig data, analysis, interpretation of
               data and writting of the manuscript.
   186   187   188   189   190   191   192   193   194   195   196